Danske Bank’s Citius Pharmaceuticals CTXR Stock Holding History

Danske Bank’s Portfolio CTXR Stock Details CTXR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2	Closed	-$8	–	1393
2024 Q4	$8	Buy	+2	New	+$13	﹤0.01%	1347

Other funds holding CTXR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BCA

Bay Colony Advisors Concord, Massachusetts $903M AUM 33.67% 1-Year Est. Return

AWA

Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Danske Bank's CTXR Position: Q1 2025 in Review

Danske Bank sold out of Citius Pharmaceuticals (CTXR) in Q1 2025, closing a stake of 2 shares — an estimated $8 sold.

Danske Bank first reported a position in CTXR in Q4 2024 and held it in 1 quarter. The position peaked at $8 in Q4 2024. 28 funds tracked by Wall St. Rank hold CTXR as of Q1 2025.

Danske Bank reported no remaining Citius Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Danske Bank sold 2 Citius Pharmaceuticals shares in Q1 2025, an estimated $8.
Danske Bank first reported a position in Citius Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Danske Bank's Citius Pharmaceuticals position peaked at $8 in Q4 2024.
28 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2025.

Based on Danske Bank's 13F filing for Q1 2025, filed 18 Dec 2025.